|Bid||3.9000 x 1300|
|Ask||3.9100 x 1200|
|Day's Range||3.7700 - 3.9300|
|52 Week Range||3.0000 - 5.4000|
|Beta (3Y Monthly)||1.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 14, 2019 - Aug 19, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]
Every investor in Accuray Incorporated (NASDAQ:ARAY) should be aware of the most powerful shareholder groups...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The main aim of stock picking is to find the market-beating stocks. But every investor is virtua...
SUNNYVALE, Calif., May 1, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that the company has signed an agreement with Hong Kong Sanatorium & Hospital (HKSH) for the acquisition of two Synchrony® motion tracking and correction technology upgrades, to be used with the hospital's Radixact® Systems. Synchrony is a sophisticated tool developed to make it easier to provide precise radiation treatments to all tumors, even those that move.
SUNNYVALE, Calif., April 24, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today the launch of its Synchrony® motion tracking and correction technology1 to be used with the Radixact® System. This new feature adds intrafraction motion synchronization capabilities to the Radixact System, enabling real-time tracking, visualization and correction for tumor motion during treatment, with the goal of improving dose accuracy and treatment times compared to conventional radiation therapy systems.
Accuray (ARAY) delivered earnings and revenue surprises of 75.00% and -0.76%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Sunnyvale, California-based company said it had a loss of 1 cent per share. The radiation oncology company posted revenue of $103.2 million in the period. Accuray expects full-year revenue in the range ...
SUNNYVALE, Calif. , April 23, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the third quarter of fiscal 2019 ended March 31, 2019 . Fiscal Third Quarter ...
NEW YORK, NY / ACCESSWIRE / April 23, 2019 / Accuray Incorporated (NASDAQ: ARAY ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on April 23, 2019 at 4:30 PM ...
Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Accuray Incorporated's (NASDAQ:ARAY): Accuray Incorporated designs, develops, and sells radiosurgery and radiation ther...
SUNNYVALE, Calif. , April 2, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its third quarter ended March 31, 2019 on Tuesday, April 23, 2019 after the market close. Management ...
SUNNYVALE, Calif., Feb. 22, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that data from an international, randomized, 38-center trial (PACE - Prostate Advances in Comparative Evidence) show that treatment with stereotactic body radiation therapy (SBRT) results in a similar safety profile to conventional radiation in men with low- or intermediate-risk prostate cancer. The study was presented during an oral session at the recent American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco, California. SBRT involves the delivery of very high doses of externally-administered radiation over a small number of treatment sessions, offering convenience for patients, compared to conventional radiation therapy which requires a substantially longer course of treatment.